
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is positioned for success with their diverse pipeline and expertise in protein engineering, with potential for blockbuster success and data releases for their lead program and bispecific antibody in development. Although there are potential risks and exclusions in their current clinical trials, there is still strong investor interest and confidence in the company's potential treatments for IBD and other inflammatory and immune-mediated diseases.
Bears say
Shattuck Labs is facing a negative outlook based on their limited pipeline, with only one candidate in Phase 2 development for Crohn's disease, and their reliance on a single target pathway that is being explored by multiple companies. The high failure rate of treatments for inflammatory diseases, coupled with the competitive landscape, raises concerns about the success of Shattuck Labs' efforts and their potential for financial success in the long run. Additionally, the company's limited pipeline and lack of diversity in its drug development efforts may hinder its ability to pivot and adapt to changes in the market and regulatory landscape.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares